Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5003 - HER2 alterations is associated with higher tumor mutation burden in gastric cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy

Tumour Site

Gastric Cancer

Presenters

Bo Wei

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

B. Wei1, Z. Li2, Q. Han3, X. Xing4, Y. Hao5, J. Zhou6, Y. Zhang7, S. Cai7, Y. Gu8

Author affiliations

  • 1 Department Of Gastrointestinal Surgery, The Third affiliated hospital, Sun Yat-Sen University, 510630 - Guangzhou/CN
  • 2 The Department Of Gastrointestinal Surgery, Beijing Cancer Hospital, 100089 - Beijing/CN
  • 3 Department Of Oncology, The General Hospital of People’s Liberation Army(301 hospital), 100853 - Beijing/CN
  • 4 Department Of Hematology And Breast Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 - Shengyang/CN
  • 5 Department Of General Surgery, Southwest Hospital, 400038 - Chongqing/CN
  • 6 Gastrointestinal Surgery, Peking University People's Hospital, 100044 - Beijing/CN
  • 7 The Medical Department, 3D Medicines Co., Ltd, 201114 - Shanghai/CN
  • 8 Department Of Oncology, Jiangsu Province Hospital, 210029 - Nanjing/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5003

Background

Immunotherapy has been proven to be effective in gastric cancer (GC) patients. But the efficacy of immunotherapy for HER2 positive GC has not been defined. Tumor mutation burden (TMB) has been considered as predictive biomarkers of immunotherapy. However, the association between HER2 alterations and TMB in GC is still unclear. We therefore analyzed the associated between HER2 alterations and TMB in Chinese patients with GC.

Methods

Genomic profiling of DNA from fresh or FFPE tumor tissue of 163 Chinese GC was performed using next-generation sequencing on 381 cancer associated genes in 3D Medicines laboratory. Whole-exome sequencing and Genomic Identification of Significant Targets in Cancer (GISTIC) data of 435 GC from The Cancer Genome Altas (TCGA) were also analyzed to evaluate the association between HER2 alterations with TMB. TMB was defined as number of somatic non-synonymous mutations in coding region. HER2 amplification in TCGA was defined as “2” derived from the copy-number analysis algorithms GISTIC.

Results

HER2 alterations including amplification, missense and fusion were present in 11.0% (18/163) of Chinese cohort and 17.0% (74/435) of TCGA cohort. 5.5% (9/163) of Chinese cohort and 14.3% (62/435) of TCGA cohort harbored HER2 amplification. Higher TMB level was observed in patients carrying any HER2 alterations (P = 0.004) in Chinese cohort, but the association was not found in TCGA cohort (P = 0.379). Prognosis analysis was also performed on patients in TCGA cohort. HER2 status was not an independent risk factors affecting disease free survival (HR, 1.007; 95%CI 0.60-1.69; P = 0.979) or overall survival (HR, 0.828; 95%CI 0.56-1.24; P = 0.357). Higher TMB level was associated with significantly better disease free survival (median, 43.04 vs. 25.53 months; HR, 0.685; 95%CI 0.47-1.00; P = 0.048) and a borderline improvement in overall survival (median, 42.51 vs. 25.69 months; HR, 0.75; 95%CI 0.56-1.02; P = 0.070).

Conclusions

HER2 alterations are associated with higher TMB in Chinese GC patients, but not in patients from TCGA. Chinese GC patients may exhibit distinct characteristics. Further studies are warranted to evaluate the efficacy of immunotherapy in GC patients with HER2 alterations.

Clinical trial identification

Legal entity responsible for the study

Yanhong Gu.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.